In various cancer cell lines (A431, MDA-MB-231, and A549 lung carcinoma) treated with gefitinib, we observed an increase in total CD151 protein levels in a dose- and time-dependent manner (Figs. 3a, c, Supplemental Fig. 4a). This evidence concerns the gene CD151 and lung carcinoma.